Lannett Company, Inc.

Lannett Company, Inc.

LCI

LCILannett Company, Inc. US flag

New York Stock Exchange

0.69

USD

- -

- -

7.38MMarket Cap

Lannett Company, Inc.

LCI

(New York Stock Exchange)

Recent

price

0.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Baijin Life Science Holdings Limited (MNNGF)
Nextleaf Solutions Ltd. (OILFF)
Veerhealth Care Limited (VEERHEALTH.BO)
Jinling Pharmaceutical Company Limited (000919.SZ)
Krka, d. d. (KRK.WA)
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
Business: Lannett Company, Inc. (NYSE: LCI) develops, manufactures, packages, markets and distributes generic versions of branded pharmaceutical products primarily in the United States; the company offers solid oral and extended-release dosage forms, topical, liquid, nasal, oral solutions, ophthalmic, patch, foam, buccal, sublingual, suspensions, soft gel, injectable and oral products addressing therapeutic areas including analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary and others; key products encompass Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants and cocaine hydrochloride solution, with expertise in complex generics, DEA-controlled substances, non-opioid ADHD treatments and generic liquids; Lannett operates as a contract development and manufacturing organization with annual capacity for approximately 3.6 billion oral solid doses and 2.0 million liters of liquids across a 425,000 square foot cGMP-compliant facility; the company sells to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations. Founded in 1942 and headquartered in Trevose, Pennsylvania, Lannett maintains manufacturing, research and development, packaging and distribution facilities in Pennsylvania and Indiana. In 2025, Aurobindo Pharma USA, a subsidiary of Aurobindo Pharma Ltd., enters a definitive agreement to acquire Lannett for an enterprise value of $250 million on a cash-free, debt-free basis from Lannett Seller Holdco, strengthening Aurobindo's U.S. manufacturing footprint, product portfolio in ADHD therapeutics and complex generics, and contract manufacturing capabilities; the transaction, subject to regulatory approvals including U.S. Federal Trade Commission clearance, anticipates completion within 8 to 12 months and aligns with reshoring trends given Lannett's excess capacity and trailing twelve-month revenues of $306 million ending March 2025.

Company News